Sharda Cropchem Limited INVESTOR PRESENTATION Q4 & FY21 Results Update



**Sharda Cropchem Limited** 







PAGE NO.	CONTENTS
03	Q4 & FY21 RESULT HIGHLIGHTS
12	CONSOLIDATED FINANCIALS
15	COMPANY OVERVIEW
20	BUSINESS MODEL
22	BUSINESS STRATEGY & OUTLOOK










## Q4 & FY21 Result Highlights









Revenues grew by 24.2% YoY to ₹ 10,881 mn in Q4 FY21 Gross profit grew marginally by 7.3% YoY to

marginally by 7.3% YoY to ₹ 3,410 mn in Q4 FY21.

Gross margin contracted by 495bps YoY from 36.3% in Q4 FY20 to 31.3% in Q4 FY21 due to exceptionally higher gross margins in Q4FY20 driven by favourable product mix

**EBITDA** grew by 5.5% YoY from ₹ 2,331 mn in Q4 FY20 to ₹ 2,460 mn in Q4 FY21


by 400bps YoY to 22.6% in Q4 FY21 mainly due to unfavourable product mix

PBT grew by 20.8% YoY from ₹ 1,381 mn in Q4 FY20 to ₹ 1,669 mn in Q4 FY21 mainly due to revenue growth, decline in forex loss and rise in other income PAT declined by 5.5% YoY from ₹ 1,417 mn in Q4 FY20 to ₹ 1,339 mn in Q4 FY21

**PAT margin** contracted by 386bps YoY to 12.3% in Q4 FY21 mainly due to lower effective tax rates in FY20

<sup>\*</sup> EBITDA excluding IA & IAUD write-off (₹ 296.7 mn in Q4 FY21 and ₹ 523.3 mn in Q4 FY20) (IA & IAUD – Intangible Assets & Intangible Assets Under Development)





YoY to ₹ 23,956 mn in FY21

Gross profit grew by 23.6% YoY to ₹ 7,597 mn in FY21. Gross margin expanded by 104bps YoY from 30.7% in FY20 to 31.7% in FY21 due to favourable product mix & higher sales in Europe region

**EBITDA** grew by 29.8% YoY from ₹ 3,506 mn in FY20 to ₹ 4,552 mn in FY21


**EBITDA margin** expanded by 150bps YoY to 19.0% in FY21 mainly due to favourable product mix and operating efficiencies PBT grew by 67.4% YoY from ₹ 1,849 mn in FY20 to ₹ 3,095 mn in FY21 due to impressive YoY revenue growth and forex gains in FY21 as against forex loss in FY20

**PAT** grew by 39.2% YoY from ₹ 1,647 mn in FY20 to ₹ 2,292 mn in FY21

**PAT margin** expanded by 135bps YoY to 9.6% in FY21


<sup>\*</sup> EBITDA excluding IA & IAUD write-off (₹ 383.2 mn in FY21 and ₹ 546.5 mn in FY20) (IA & IAUD – Intangible Assets & Intangible Assets Under Development)








#### **Q4 FY21 YoY ANALYSIS: REVENUE BREAKUP**



- ➤ Agrochemicals revenues during Q4 FY21 grew by 22.1% YoY
- ➤ Non-Agrochemicals revenues during Q4 FY21 grew by 56.1% YoY
- ➤ Revenue Mix:
  Agrochemicals: Non-Agrochemicals mix stood at 92:8 in Q4 FY21 & 94:6 in Q4 FY20

#### FY21 YoY ANALYSIS: REVENUE BREAKUP



- ➤ Agrochemicals revenues during FY21 grew by 22.2% YoY
- ➤ Non-Agrochemicals revenues during FY21 grew by 6.0% YoY
- ➤ Revenue Mix:


Agrochemicals: Non-Agrochemicals mix stood at 86:14 in FY21 & 84:16 in FY20





Fungicides, 3,056

Insecticides, 1,707



Q4 FY21 Revenue Growth: Europe: 14.4%, NAFTA: 34.8%, RoW: 5.8% & LATAM 46.2%

**Europe**, 5,353

NAFTA, 3,859

LATAM, 402

RoW, 434

Formulation: Al MixQ4 FY21 – 95:5Q4 FY20 – 96:4

Formulations, 9,539

Product Mix updates: Herbicides continues to command 52.6% of revenues in Q4 FY21 & 52.6% of revenues in Q4 FY20

Herbicides, 5,285







**REGION WISE** 


FORMULATION VS. AI

FY20: Agrochemicals Revenues: 16,850


PRODUCT WISE








FY21: Agrochemicals Revenues : 20,585








> FY21 Revenue Growth:

Europe: 20.0%, NAFTA: 26.0%, LATAM: 24.6% & ROW: 17.1%

Formulation: Al Mix

FY21 – 93:7 FY20 – 92:8 Product Mix updates: Herbicides continues to command 51.3% of revenues in FY21 & 50.6% of revenues in FY20






- ➤ Europe grew by 35.7% in Q4 FY21 to ₹ 265 mn
- ➤ NAFTA grew by 57% in Q4 FY21 to ₹ 352 mn
- ➤ LATAM grew by 215.2% in Q4 FY21 to ₹ 59 mn
- ➤ RoW grew by 64.8% in Q4 FY21 to ₹ 158 mn

- ➤ Europe grew by 22.4% in FY21 to ₹ 1,076 mn
- ➤ NAFTA grew by 12.7% in FY21 to ₹ 1,488 mn
- ➤ LATAM grew by 87.1% in FY21 to ₹ 239 mn
- ➤ RoW declined by 33.4% in FY21 to ₹ 568 mn



#### WORKING CAPITAL DAYS\*

#### **NET WORKING CAPITAL DAYS**





➤ Net working capital days stood at 86 days in FY21 as against 74 days in FY20



### **Consolidated Financials**





Particulars	Q4 FY21	Q4 FY20	YoY %	FY21	FY20	YoY%
Revenue from Operations	10,881.4	8,760.7	24.2%	23,956.1	20,030.2	19.6%
cogs	7,471.5	5,581.4	33.9%	16,359.6	13,886.1	17.8%
Gross Profit	3,409.9	3,179.3	7.3%	7,596.5	6,144.1	23.6%
Gross Margin %	31.3%	36.3%	495bps	31.7%	30.7%	104bps
Employee Expenses	118.6	116.5	1.8%	373.2	349.0	7.0%
Other Expenses	1,128.4	1,255.2	10.1%	3,054.8	2835.7	7.7%
EBITDA*	2,459.6	2,330.9	5.5%	4,551.7	3,505.9	29.8%
EBITDA Margin %	22.6%	26.6%	400bps	19.0%	17.5%	150bps
Forex (Gain)/Loss	131.5	179.5	26.8%	(198.9)	151.4	N.A.
Depreciation	522.2	350.0	49.2%	1,704.4	1,371.2	24.3%
Finance Cost	7.7	4.5	71.9%	27.7	19.2	44.6%
Other Income	167.6	107.9	55.4%	459.3	431.1	6.5%
PBT	1,669.2	1,381.4	20.8%	3,094.5	1,848.7	67.4%
Tax Expense	329.9	(35.5)	N.A.	802.3	201.8	297.7%
PAT	1,339.3	1,416.8	5.5%	2,292.2	1,646.9	39.2%
PAT Margin %	12.3%	16.2%	386bps	9.6%	8.2%	135bps
Earnings Per Share (EPS) In ₹	14.84	15.70	5.5%	25.40	18.25	39.2%

<sup>\*</sup> EBITDA excluding IA & IAUD write-off (₹ 296.7 mn in Q4 FY21, ₹ 523.3 mn in Q4 FY20, ₹ 383.2 mn in FY21 and ₹ 546.5 mn in FY20) (IA & IAUD – Intangible Assets & Intangible Assets Under Development)

# **FY21: CONSOLIDATED BALANCE SHEET**



In ₹ Mn

Particulars	FY21	FY20	Particulars	FY21	FY20
Equities & Liabilities			Assets		
Shareholder's Funds			Non-Current Assets		
Equity and Share Capital	902.2	902.2	Property, Plant and Equipment	208.8	278.2
Other Equity	15,240.8	13,125.7	Goodwill	4.3	4.4
Non-controlling Interest	3.1	2.7	Other Intangible assets	5,231.1	3,880.8
Total Equity	16,146.1	14,030.6	Intangible assets under development	•	· ·
Name O assessed I feel street				1,310.4	1,614.0
Non-Current Liabilities			Deferred Tax Assets (net)	60.4	39.2
Borrowings	-	0.9	Non-Current Tax Assets	736.3	725.3
Trade Payables	24.0	23.8	Other non-current assets	94.0	115.5
Other Financial Liabilities	116.0	130.6	Total non-current assets	7,645.3	6,657.4
Provisions	30.2	26.6		.,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Deferred Tax Liabilities (net)	928.7	693.0	Current Assets		
Total non-current liabilities	1,098.9	874.9			
			Inventories	5,255.5	3,822.4
Current Liabilities			Investments	830.1	1,155.3
Borrowings	678.5	-	Trade Receivables	11,625.7	9,893.9
Trade Payables	8,067.5	6,866.9	Cash & Cash equivalents	855.5	777.6
Other Financial Liabilities	1,535.9	897.2	Other Bank balances	1,749.8	756.9
Other Current Liabilities	580.0	543.5	Other Financial Assets	280.6	112.8
Current Tax Liabilities	31.7	15.2	Other Current Assets		_
Provisions	500.0	243.9		396.1	295.9
Total current Liabilities	11,393.6	8,566.7	Total current assets	20,993.3	16,814.8
Total Equity & Liabilities	28,638.6	23,472.2	Total Assets	28,638.6	23,472.2



## **Company Overview**



### **COMPANY'S SNAPSHOT**



#### **Agrochemicals Focused Company**

Intellectual Property (IP) driven company engaged in marketing and distribution of wide range formulations and generic active ingredients

#### **Asset-Light Business Model**

The Company efficiently channelises its time and resources for strengthening its core competency of identifying generic molecules and registration opportunities which offers scalable growth with limited capital requirements

#### Firm Registration Pipeline

The Company has procured 2,543 registrations\* [2,270 registrations - Formulations and 273 registrations - Active Ingredients (Als)]. Additionally, it has filed 1,128 applications for registrations globally pending at different stages

\*As on 31st March, 2021

#### **Diversified Sourcing Arrangements**

Enduring relationship with multiple manufacturers and formulators enables the Company to source and supply formulations or generic active ingredients at competitive prices

# Consistently Increasing Global Presence

With its diversified range of product portfolio, the Company has grown by expanding its business operations in 80+ countries, across Europe, NAFTA, Latin America and Rest of the World

#### **Wide-spread Distribution Network**

Presence in the entire agrochemical value chain with 500 third-party distributors and 400+ sales force serving the Company's esteemed clientele in 80+ countries

#### **Prudent and Professional Management**

The Company's apt domain knowledge and experience gives a substantial competitive advantage for expanding its business in existing markets and entering new geographies

#### **Sound Financial Standing**

Sharda Cropchem is a debt-free company which enables the Company to utilise its cash flows prudently

#### Financial Performance

Sales – 14.4% (FY17-21 CAGR) ROCE – 16.0% (FY21), ROE – 15.2% (FY21) and Net Cash & Cash Equivalents - INR 3,435 mn (FY21)



### Presence in 80+ countries across Europe, NAFTA, LATAM & RoW




FY21 CAPEX: INR 3,090 Mn


## **KEY FINANCIAL PERFORMANCE INDICES**







#### In ₹ Mn








\* EBITDA excluding IA & IAUD write-off





Source: PAT Margin = PAT / Revenue from Operations, EBITDA Margin = EBITDA / Revenue from Operations, ROE: PAT/Avg. Equity, ROCE: EBIT/Avg. Capital Employed [(Capital Employed = Equity + Total Debt)]


# **SHAREHOLDING STRUCTURE**



KEY INSTITUTIONAL INVESTORS – 31 <sup>ST</sup> MAR 2021	% HOLDING
HDFC MF	9.22%
L & T Mutual Fund	4.55%
DSP MF	2.89%
Pinebridge Global	1.96%

MARKET DATA	AS ON 25 <sup>TH</sup> May 2021
Market capitalization (INR Mn)	32,055
Price (INR)	355.3
No. of shares outstanding (Mn)	90.2
Face Value (INR)	10.0
52 week High-Low (INR)	374.0 – 134.6

#### **SHAREHOLDING – 31<sup>ST</sup> MARCH 2021**



Source: BSE





## **Business Model**



## DIFFERENTIATED ASSET LIGHT BUSINESS MODEL





#### **Agrochemical Value Chain**

Sharda's Operating Area

Basic & Applied Research

Identification

Registration

Active Ingredient Manufacturing

Formulation & Packaging

Marketing & Distribution

#### **ASSET LIGHT BUSINESS MODEL**

- Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third party distributors and/or own sales
- Manufacturing of Als and formulations is outsourced
- ➤ Highly flexible operating model resulting in
  - Overall cost competitiveness
  - ➤ Efficient management of fluctuating market demand across various geographies.
  - Offering wide range of formulations and Als




**Customer &** 

**Products** 

Sharda's Model:

**Demand Pulled / Customer Driven** 



Sharda is a focussed global agrochemical marketing & distribution company



## **Business Strategy & Outlook**



## **BUSINESS STRATEGY & OUTLOOK**





- Leverage market presence and execution capabilities
- ➤ Adopt the factory-to-farmer approach and be a one-stop solution provider
- Strategy on-ground in Mexico, Colombia, Hungary, Spain, Poland, Italy, Portugal, USA & India

### Expand & Strengthen Distribution Presence

- > Expand geographical reach using existing library of dossiers
- Two-fold strategy of further penetrating existing markets and entering new markets

### Continual Investment in Obtaining Registrations

- > Continue to identify generic molecules going off- patent
- > Investing in preparing dossiers and seeking registrations in own name

### Focus on Biocide Registrations

- Scale up marketing and distribution of biocides with a focus on Europe
- Increase biocide registrations

02

03

04

# FOR FURTHER QUERIES



